MADRIGAL PHARMACEUTICALS, INC. Payments of Debt Issuance Costs
MADRIGAL PHARMACEUTICALS, INC. (MDGL) reported Payments of Debt Issuance Costs of $10.41 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsOfDebtIssuanceCosts · last filed 2026-02-19
- MADRIGAL PHARMACEUTICALS, INC. payments of debt issuance costs for the quarter ending 2025-12-31 was $983.00K.
- MADRIGAL PHARMACEUTICALS, INC. payments of debt issuance costs for the quarter ending 2024-12-31 was $0.00.
- MADRIGAL PHARMACEUTICALS, INC. payments of debt issuance costs for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. payments of debt issuance costs for the quarter ending 2024-06-30 was $0.00, a 100.00% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. payments of debt issuance costs for fiscal 2025 was $10.41M.
- MADRIGAL PHARMACEUTICALS, INC. payments of debt issuance costs for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- MADRIGAL PHARMACEUTICALS, INC. payments of debt issuance costs for fiscal 2023 was $363.00K, a 59.03% decline from fiscal 2022.
- MADRIGAL PHARMACEUTICALS, INC. payments of debt issuance costs for fiscal 2022 was $886.00K.
| Period end | Payments of Debt Issuance Costs 3 month | Payments of Debt Issuance Costs 6 month | Payments of Debt Issuance Costs 9 month | Payments of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2025-12-31 | $983.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $10.41M 10-K · filed 2026-02-19 | ||
| 2025-09-30 | $9.42M 10-Q · filed 2025-11-04 | |||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $0.00 derived: sum of 3 quarters · filed 2026-02-19 | $0.00 10-K · filed 2026-02-19 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2025-11-04 | $0.00 10-Q · filed 2025-11-04 | $0.00 derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $0.00 10-Q · filed 2024-08-07 | $0.00 derived: sum of 3 quarters · filed 2026-02-19 | $75.00K derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-07 | $0.00 derived: sum of 2 quarters · filed 2026-02-19 | $75.00K derived: sum of 3 quarters · filed 2026-02-19 | $150.00K derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $75.00K derived: sum of 2 quarters · filed 2026-02-19 | $150.00K derived: sum of 3 quarters · filed 2026-02-19 | $363.00K 10-K · filed 2026-02-19 |
| 2023-09-30 | $75.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $150.00K derived: sum of 2 quarters · filed 2024-10-31 | $363.00K 10-Q · filed 2024-10-31 | $363.00K derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $75.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $288.00K 10-Q · filed 2024-08-07 | $288.00K derived: sum of 3 quarters · filed 2025-02-26 | $288.00K derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $213.00K 10-Q · filed 2024-05-07 | $213.00K derived: sum of 2 quarters · filed 2025-02-26 | $213.00K derived: sum of 3 quarters · filed 2025-02-26 | $1.10M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $0.00 derived: sum of 2 quarters · filed 2025-02-26 | $886.00K derived: sum of 3 quarters · filed 2025-02-26 | $886.00K 10-K · filed 2025-02-26 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $886.00K derived: sum of 2 quarters · filed 2023-11-06 | $886.00K 10-Q · filed 2023-11-06 | $886.00K derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $886.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $886.00K 10-Q · filed 2023-08-08 | $886.00K derived: sum of 3 quarters · filed 2024-02-28 | $886.00K derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | $0.00 derived: sum of 2 quarters · filed 2024-02-28 | $0.00 derived: sum of 3 quarters · filed 2024-02-28 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $0.00 derived: sum of 2 quarters · filed 2024-02-28 | $0.00 10-K · filed 2024-02-28 | |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $0.00 10-Q · filed 2022-11-03 | ||
| 2021-06-30 | $0.00 10-Q · filed 2022-08-04 | |||
| 2020-12-31 | $0.00 10-K/A · filed 2023-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |